ScoreWhy is C4 Therapeutics, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 1.60% and Operating profit at -22.96% over the last 5 years
2
Flat results in Jun 26
- NET SALES(Q) At USD 6.64 MM has Fallen at -23.8%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 2.11%, its profits have risen by 8.4%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -1.68% over the previous quarter and currently hold 8.44% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
5
Underperformed the market in the last 1 year
- The stock has generated a return of 2.11% in the last 1 year, much lower than market (S&P 500) returns of 15.36%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is C4 Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
C4 Therapeutics, Inc.
2.11%
-0.34
87.57%
S&P 500
15.36%
1.17
13.09%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
1.60%
EBIT Growth (5y)
-22.96%
EBIT to Interest (avg)
-76.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.14
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.92
EV to EBIT
0.07
EV to EBITDA
0.07
EV to Capital Employed
-0.49
EV to Sales
-0.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-36.74%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at USD -48.76 MM
RAW MATERIAL COST(Y)
Fallen by -7.94% (YoY
-3What is not working for the Company
NET SALES(Q)
At USD 6.64 MM has Fallen at -23.8%
Here's what is working for C4 Therapeutics, Inc.
Net Profit
Higher at USD -48.76 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -7.94% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for C4 Therapeutics, Inc.
Net Sales
At USD 6.64 MM has Fallen at -23.8%
over average net sales of the previous four periods of USD 8.72 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
